Market closed

Natera/$NTRA

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Ticker

$NTRA

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Austin, United States

Employees

3,288

Website

www.natera.com

Natera Metrics

BasicAdvanced

$22B

-

-$1.76

1.53 -

Price and volume

Market cap

$22B

Beta

1.53

52-week high

$183.00

52-week low

$59.80

Average daily volume

1.1M

Financial strength

Current ratio

4.388

Quick ratio

4.078

Long term debt to equity

43.881

Total debt to equity

54.151

Interest coverage (TTM)

-19.30%

Management effectiveness

Return on assets (TTM)

-9.96%

Return on equity (TTM)

-25.82%

Valuation

Price to revenue (TTM)

13.449

Price to book

23.92

Price to tangible book (TTM)

23.92

Price to free cash flow (TTM)

-471.669

Growth

Revenue change (TTM)

54.94%

Earnings per share change (TTM)

-60.69%

3-year revenue growth (CAGR)

39.46%

3-year earnings per share growth (CAGR)

-27.48%

What the Analysts think about Natera

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Natera stock.

Natera Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Natera Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Natera News

AllArticlesVideos

Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

Business Wire·2 days ago

Natera: Poised For A Great Future But I'd Wait For A Pullback

Seeking Alpha·2 weeks ago

Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients

Business Wire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NTRA

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Natera stock?

Natera (NTRA) has a market cap of $22B as of January 15, 2025.

What is the P/E ratio for Natera stock?

The price to earnings (P/E) ratio for Natera (NTRA) stock is 0 as of January 15, 2025.

Does Natera stock pay dividends?

No, Natera (NTRA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Natera dividend payment date?

Natera (NTRA) stock does not pay dividends to its shareholders.

What is the beta indicator for Natera?

Natera (NTRA) has a beta rating of 1.53. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.